Abbott Laboratories (ABT)
What Drove Abbott's Q3?
Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations. The company reported revenue of $10.64 billion and earnings of $1.21 on a per-share and adjusted basis, compared to our estimates of $10.55 billion and $1.20, respectively.
Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Abbott Laboratories is a diversified healthcare company with strong segments, particularly Medical Devices, contributing to steady growth and consistent dividends. ABT's Q2 earnings showed solid performance, with Medical Devices leading organic revenue growth, despite some segments facing challenges including discontinuing products and COVID-19 sales decline. The company authorized a new $7 billion buyback program, reinforcing its commitment to returning cash to shareholders through dividends and share repurchases.
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
These companies' longtime shareholders have generally been rewarded.
3 Fortune 500 Industry Leaders Boast Ideal October Dividends
The June/July 2024 edition of Fortune revealed the 500 biggest U.S. companies by revenue and profits. Dogcatcher's quest to sniff-out the best dividend-buys focused on 66 industry-leader profits per YCharts data 10/16/24. Those 66 industry leaders were segmented into 21 business sectors, ranging (alphabetically) from apparel to wholesalers. 3 of the 66 were private or foreign exchange listed firms, not tracked by YCharts, leaving 63-listed. 57 dividend-yielding stocks led those 63 industry leaders and ranged 0.03% to 8.13% in annual yield and ranged -12.12% to 55.72% in broker-estimated one-year target-price-upsides.
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
These stocks could deliver big over the long term.
Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
On Wednesday, Abbott Laboratories ABT reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion.
Abbott's Growth and Dividends Make It a Smart Portfolio Pick
There are many reasons to own Abbott Laboratories ABT, but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among healthcare names.
These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings
Abbott Laboratories ABT reported better-than-expected third-quarter results on Wednesday.
Is Abbott Laboratories Stock a Buy?
The healthcare stock is lagging the market this year.
Wake Up, It's Time To Pick Stocks: Here Are 2 Dividend Stocks I Love
This article emphasizes the importance of stock picking in today's market, where elevated valuations and sector rotations make it essential for generating returns. I've identified two dividend stocks that stand out due to their strong fundamentals and growth potential. These selections cater to income investors seeking stability. By focusing on unique opportunities, I aim to navigate the market effectively. These dividend picks combine reliable income with promising growth prospects for long-term success.
Abbott Laboratories: It's No Longer A Buy For Now
Since my previous article, shares of Abbott Laboratories have returned 10% versus the 7% gains of the S&P 500 index. The healthcare company's sales and adjusted diluted EPS rose in the third quarter. Abbott Laboratories maintains a fortress-like balance sheet.
